Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


One year on, J&J's Synthes buy finally gets EU green light

This article was originally published in Clinica

Executive Summary

The finishing line is now in sight for Johnson & Johnson's planned billion-dollar acquisition of trauma specialist Synthes, after European anti-trust regulators finally approved the takeover. J&J agreed to buy Synthes for €19bn nearly a year ago ($21.3bn based on the exchange rate at that time) in a deal that would strengthen its leading position in the global orthopaedics market and catapulting it to the number-one spot in the $5.5bn trauma device market (, 27 April 2011).





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts